These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 16363426)

  • 1. [Metabolic syndrome and cardiovascular risk].
    Charbonnel B
    Rev Prat; 2005 Oct; 55(16):1765-71. PubMed ID: 16363426
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Is the metabolic syndrome still a useful entity?].
    Charbonnel B
    Rev Prat; 2010 Apr; 60(4):478-84. PubMed ID: 20465120
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PPARs as targets for the modulation of cardiovascular risk factors associated with the metabolic syndrome.
    Fernandez AZ
    Curr Opin Investig Drugs; 2004 Sep; 5(9):936-40. PubMed ID: 15503647
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Cardiovascular disease and metabolic syndrome].
    Maranghi M; Coletta P; Durante C; Pergolini D; Filetti S
    Recenti Prog Med; 2006 Dec; 97(12):719-26. PubMed ID: 17252730
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Importance of diagnosing and treating the metabolic syndrome in reducing cardiovascular risk.
    Smith SR
    Obesity (Silver Spring); 2006 Jun; 14 Suppl 3():128S-134S. PubMed ID: 16931494
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Insulin resistance and the metabolic syndrome as predictors of cardiovascular risk: where are we now?
    Sattar N
    Minerva Endocrinol; 2005 Sep; 30(3):121-38. PubMed ID: 16208304
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolic syndrome, new onset diabetes, and new end points in cardiovascular trials.
    Haffner SM; Ruilope L; Dahlöf B; Abadie E; Kupfer S; Zannad F
    J Cardiovasc Pharmacol; 2006 Mar; 47(3):469-75. PubMed ID: 16633092
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Angiotensin receptor blockers: Cardiovascular protection in the metabolic syndrome.
    Deedwania PC; Schmieder R
    J Renin Angiotensin Aldosterone Syst; 2006 Jun; 7 Suppl 1():S12-8. PubMed ID: 16986230
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oxidative stress as pathogenesis of cardiovascular risk associated with metabolic syndrome.
    Otani H
    Antioxid Redox Signal; 2011 Oct; 15(7):1911-26. PubMed ID: 21126197
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolic syndrome in the prevention of cardiovascular diseases and diabetes--still a matter of debate?
    Ma X; Zhu S
    Eur J Clin Nutr; 2013 May; 67(5):518-21. PubMed ID: 23403882
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The progression of cardiovascular risk to cardiovascular disease.
    Rosin BL
    Rev Cardiovasc Med; 2007; 8 Suppl 4():S3-8. PubMed ID: 17934392
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular mechanisms for vascular injury in the metabolic syndrome.
    Yamagishi S; Nakamura K; Jinnouchi Y; Takenaka K; Imaizumi T
    Drugs Exp Clin Res; 2005; 31(3):123-9. PubMed ID: 16033251
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [From "deadly quartet" to "metabolic syndrome". An analysis of its clinical relevance].
    Vancheri F; Burgio A; Dovico R
    Recenti Prog Med; 2007 Mar; 98(3):192-200. PubMed ID: 17484168
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Hypertension and the metabolic syndrome].
    Olsen MH; Jeppesen J; Larsen ML
    Ugeskr Laeger; 2009 Jun; 171(25):2107-9. PubMed ID: 19671392
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolic syndrome, cardiovascular disease and type-2 diabetes.
    Bano KA; Batool A
    J Pak Med Assoc; 2007 Oct; 57(10):511-5. PubMed ID: 17990428
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Insulin resistance and cardiovascular disease: the role of PPARgamma activators beyond their anti-diabetic action.
    Walcher D; Marx N
    Diab Vasc Dis Res; 2004 Oct; 1(2):76-81. PubMed ID: 16302645
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The metabolic syndrome: evolving evidence that thiazolidinediones provide rational therapy.
    Wyne KL
    Diabetes Obes Metab; 2006 Jul; 8(4):365-80. PubMed ID: 16776743
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of high-dose atorvastatin on the cardiovascular risk associated with individual components of metabolic syndrome: a subanalysis of the Treating to New Targets (TNT) study.
    Deedwania PC; Shepherd J; Breazna A; DeMicco DA;
    Diabetes Obes Metab; 2016 Jan; 18(1):56-63. PubMed ID: 26434404
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The link between abdominal obesity, metabolic syndrome and cardiovascular disease.
    Ritchie SA; Connell JM
    Nutr Metab Cardiovasc Dis; 2007 May; 17(4):319-26. PubMed ID: 17110092
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Unmet needs in controlling metabolic disease.
    Haffner SM
    Rev Cardiovasc Med; 2007; 8 Suppl 4():S17-24. PubMed ID: 17934390
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.